ICON plc Acquires PRA Health Sciences

Isracann Biosciences to Acquire Praesidio Health

February 23, 2022

Biotechnology

Isracann Biosciences Inc. entered into a binding letter of intent to acquire Canadian medical research company Praesidio Health Inc. under a stock transaction valued at approximately CAD 4.0 million. Praesidio develops and validates evidence-based natural health medicines (including formulations with cannabinoids and/or psilocybin) for conditions such as urological disorders, anxiety/stress, immune support and sleep.

PRA Acquires Island Style Innovations in Hawai‘i

November 25, 2024

Professional Services

PRA, a Chicago-based business events management firm majority owned by EagleTree Capital, has acquired Island Style Innovations, a Hawai‘i-based destination management and events specialist. The Island Style Innovations team will join PRA’s Hawai‘i office and rebrand as PRA to expand the company’s local capabilities and strengthen its presence in the Hawaiian meetings, conventions, and incentive market.

Certara Acquires Pinnacle 21

October 4, 2021

Software

Certara, Inc. completed the acquisition of Pinnacle 21, a provider of SaaS solutions for clinical data standardization, validation and regulatory-submission readiness. Equity holders of Pinnacle 21 received approximately $250 million in cash and 2,239,717 restricted shares of Certara common stock; Certara said the deal expands its data-sciences and software capabilities and is expected to be accretive to revenue and adjusted EBITDA.

Pratia Acquires Clinical Research Center (CRC)

January 8, 2025

Healthcare Services

Pratia, a Warsaw-based research site network and part of the Humaneva Group, has acquired Clinical Research Center (CRC), the leading clinical trial site network operating in the Czech Republic and Slovakia. The acquisition expands Pratia's geographic footprint into Slovakia, strengthens its presence in the Czech Republic, and adds CRC's site services and home-based care capabilities to support hybrid and decentralized clinical trials.

Merck Acquires Prometheus Biosciences for $10.8 Billion

June 16, 2023

Biotechnology

Merck has agreed to acquire clinical-stage biotechnology company Prometheus Biosciences for $200.00 per share in cash, representing an approximate total equity value of $10.8 billion. The acquisition strengthens Merck's immunology pipeline by adding Prometheus' precision-medicine platform and lead candidate PRA023 (MK-7240) for inflammatory bowel disease and other immune-mediated conditions.

EagleTree Capital Acquires PRA Business Events from CI Capital Partners

March 7, 2023

Professional Services

EagleTree Capital has acquired PRA, a Chicago-based leader in business event management, from CI Capital Partners. The PRA management team will remain in place and EagleTree said it will invest to expand PRA's market-leading event design, production and digital engagement capabilities; terms were not disclosed.